RT Journal Article
SR Electronic
T1 Universality in COVID-19 spread in view of the Gompertz function
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.18.20135210
DO 10.1101/2020.06.18.20135210
A1 Ohnishi, Akira
A1 Namekawa, Yusuke
A1 Fukui, Tokuro
YR 2020
UL http://medrxiv.org/content/early/2020/06/22/2020.06.18.20135210.abstract
AB We demonstrate that universal scaling behavior is observed in the current coronavirus (COVID-19) spread in various countries. We analyze the numbers of infected people in selected eleven countries (Japan, USA, Russia, Brazil, China, Italy, Indonesia, Spain,South Korea, UK, and Sweden). By using the double exponential function called the Gompertz function, fG(x) = exp(−e−x), the number of infected people is well described as N(t) = N0fG(γ(t − t0)), where N0, γ and t0 are the final total number of infected people, the damping rate of the infection probability and the peak time of dN(t)/dt, respectively. The scaled data of infected people in most of the analyzed countries are found to collapse onto a common scaling function fG(x) with x = γ(t − t0) in the range of fG(x) ± 0.05. The recently proposed indicator so-called the K value, the increasing rate of infected people in one week, is also found to show universal behavior. The mechanism for the Gompertz function to appear is discussed from the time dependence of the produced pion numbers in nucleus-nucleus collisions, which is also found to be described by the Gompertz function.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported in part by the Grants-in-Aid for Scientific Research from JSPS (Nos. 19H01898 and 19H05151).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We use data opened to public and available on the web.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe use data opened to public and available on the web. https://ourworldindata.org/coronavirus-source-data https://covidtracking.com/